הכנסה תפעולית לפני ניכוי פחת: Longeveron (LGVN)

The regenerative medicine sector currently relies on the test results of Lomecel-B against Alzheimer's disease. Longeveron Inc. (LGVN) is expanding its capacities in Florida, minimizing reliance on third-party laboratories during drug development. Actual EBITDA demonstrates the business's liquidity vector, where the 0.00 level indicates the state of the parameter. This chart smooths out market noise, helping investors determine the real cash flow.

Stable utilization of the Longeveron Inc. (LGVN) biomanufacturing complex, coupled with the uninterrupted operation of sterile zones, directly determines cash flow dynamics. Analyzing EBITDA allows for the daily tracking of real business expansion, eliminating quarterly reporting lags. While growth in this indicator confirms the issuer's fundamental strength, purchasing the asset at a local peak on the chart risks a prolonged price drawdown.